Merck lifts revenue outlook on new drug sales, cuts profit view on deal charges

• Q2 revenue reached $16.61 billion (up 5% year-over-year), with Keytruda generating $8.37 billion including $463 million from a new injectable version designed to combat patent expiration
• Newer products showed strong momentum: Winrevair sales jumped 75% to $588 million and pneumococcal vaccine Capvaxive rose 42% to $184 million
• Merck faces imminent generic competition for diabetes drugs Januvia and Janumet later in 2026 and blockbuster Keytruda in 2028, driving its acquisition strategy

Merck Q2 2025 Results: Strong Revenue Growth Offset by Acquisition-Related Profit Cuts

Merck reported second-quarter results that exceeded Wall Street expectations, with revenue reaching $16.61 billion versus the expected $16.36 billion, representing a 5% year-over-year increase. However, the pharmaceutical giant posted a net loss of $1.34 billion, or 54 cents per share, primarily due to charges related to its acquisition of biotech firm Terns Pharmaceuticals.

Revised Guidance:

• 2026 revenue outlook raised to $66.3-$67.3 billion (up from $65.8-$67 billion)
• Adjusted earnings guidance cut to $2.66-$2.76 per share (down from $5.04-$5.16)

Key Product Performance:

Keytruda, Merck's blockbuster immunotherapy, generated $8.37 billion in Q2 sales (up 5% YoY), exceeding analyst estimates of $8.27 billion. Notably, $463 million came from the new injectable version, critical to offsetting patent expiration in 2028.

Newer products demonstrated robust growth:

• Winrevair (rare lung condition treatment): $588 million, up 75% YoY
• Capvaxive (pneumococcal vaccine): $184 million, up 42% YoY
• Animal health division: $1.78 billion, beating estimates

Strategic Context:

Merck is pursuing aggressive acquisitions to counter impending generic competition for several major drugs, including diabetes medications Januvia and Janumet (facing generic competition later in 2025) and Keytruda (2028). The company recently gained approval for its first PCSK9 pill in July, part of its portfolio diversification strategy.

The results reflect a company successfully building revenue through new products while absorbing near-term profit impacts from strategic M&A activity to secure long-term growth.